Quarterly ResultApr 27, 2026, 07:16 AM
FULC Q1 Net Loss $(18.9)M; Accumulated Deficit $(613.2)M
AI Summary
Fulcrum Therapeutics reported a net loss of $(18.9) million for Q1 2026, an increase from $(17.7) million in Q1 2025, bringing its accumulated deficit to $(613.2) million. The company continues to incur significant losses and expects this trend to persist, necessitating substantial additional funding to support its clinical development of pociredir and other product candidates. Cash, cash equivalents, and marketable securities are projected to fund operations for at least 12 months.
Key Highlights
- Net loss for Q1 2026 was $(18.9) million, compared to $(17.7) million in Q1 2025.
- Accumulated deficit reached $(613.2) million as of March 31, 2026.
- Cash and cash equivalents decreased to $50.3 million from $197.5 million in Q4 2025.
- Marketable securities increased to $283.1 million from $154.8 million in Q4 2025.
- Research and development expenses rose to $14.1 million in Q1 2026 from $13.4 million in Q1 2025.
- General and administrative expenses increased to $8.1 million in Q1 2026 from $7.0 million in Q1 2025.
- Company expects current capital to fund operations for at least 12 months.
- Only one product candidate, pociredir, is currently in clinical trials.
Price Impact
More from FULC